Law M A, Josey J, Justino H, Mullins C E, Ing F F, Nugent A W
Department of Pediatrics, Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine, Fannin Houston, Texas, USA.
Catheter Cardiovasc Interv. 2009 Feb 1;73(2):190-5. doi: 10.1002/ccd.21710.
There is limited published outcome data on the STARFlex device for transcatheter closure of atrial septal defects (ASD).
To contribute to the long term outcomes of ASD device closure with the STARFlex device.
Results of a prospective FDA approved clinical trial (1999-2001) from a single institution of the STARFlex device for simple ASD was reviewed. The inclusion criteria included age >or=2 years, isolated secundum ASD, evidence of right ventricular volume overload, and maximum stretched diameter <22 mm. A retrospective review of the original study data with most recent follow-up was performed. Clinical success in the trial was defined as complete closure or residual leak <or=2 mm, absence of a severe complication and no need for an additional device or surgery to treat the ASD.
Twenty seven (27) patients were prospectively enrolled in the study period with a procedural success in 23 (85%). There were two severe complications, both 40 mm device embolizations that underwent semiurgent surgical intervention for device removal and ASD closure (40 mm device subsequently withdrawn from trial). Device placement was unsuccessful in two patients due to malposition related to an insufficient retro-aortic rim, with elective surgical closure. Unsuccessful procedural outcomes were statistically associated with deficient rims (P < 0.01). Of the 23 long term follow-up device patients, 23 (100%) achieved clinical success: 22 (96%) had complete closure at 1 year and latest echocardiographic follow-up and one case had a small <2 mm residual defect that has persisted. There have been no late complications with normalization of RV volumes in 92% and no deleterious ECG changes. Device fractures occurred in 8/23 (35%) devices and were more common in the larger devices (P < 0.05) but had no sequelae. None required any further intervention to treat the ASD and there were no infectious or thrombotic issues.
In this cohort the STARFlex device for secundum ASD closure provided procedural success in 85% with failures due to surgical referral. All 23 patients with a STARFlex device with available long term follow-up had clinical success. Further long term data is required.
关于用于经导管闭合房间隔缺损(ASD)的STARFlex装置,已发表的结局数据有限。
探讨使用STARFlex装置进行ASD封堵术的长期疗效。
回顾了一项前瞻性、经美国食品药品监督管理局(FDA)批准的临床试验(1999 - 2001年)结果,该试验在单一机构开展,使用STARFlex装置治疗单纯性ASD。纳入标准包括年龄≥2岁、孤立性继发孔型ASD、右心室容量超负荷证据以及最大伸展直径<22 mm。对原始研究数据进行回顾性分析,并进行最近一次随访。该试验中的临床成功定义为完全闭合或残余分流≤2 mm、无严重并发症且无需额外装置或手术治疗ASD。
在研究期间前瞻性纳入27例患者,23例(85%)手术成功。发生了2例严重并发症,均为40 mm装置栓塞,患者接受了半紧急手术取出装置并闭合ASD(40 mm装置随后退出试验)。2例患者因主动脉后缘不足导致装置位置不当,手术放置装置失败,改行择期手术闭合。手术失败与边缘不足在统计学上相关(P < 0.01)。在23例接受长期随访的装置植入患者中,23例(100%)获得临床成功:22例(96%)在1年时及最近一次超声心动图随访时完全闭合,1例有<2 mm的小残余缺损持续存在。未发生晚期并发症,92%的患者右心室容量恢复正常,且无有害的心电图改变。23例装置中有8例(35%)发生装置断裂,在较大装置中更常见(P < 0.05),但无后遗症。无一例需要进一步干预治疗ASD,也无感染或血栓形成问题。
在该队列中,用于继发孔型ASD闭合的STARFlex装置手术成功率为85%,失败原因是转手术治疗。所有23例接受STARFlex装置且有长期随访资料的患者均获得临床成功。还需要进一步的长期数据。